Epocrates mobile app adds disease areas

Share this article:
Epocrates mobile app adds disease areas
Epocrates mobile app adds disease areas

Epocrates expanded its mobile resource centers, adding disease-specific areas underwritten by pharma advertisers.

The resource centers, targeted to clinicians, provide medical commentaries and updates on the diagnosis and treatment of prevalent conditions, including atrial fibrillation, Alzheimer's disease, diabetes, epilepsy, infection management, pain management and venous thromboembolism, according to a company statement.

The disease-specific areas also deliver “unobtrusive branded messages” to docs, according to an Epocrates spokesperson. The application is available as a free download for Palm and Windows mobile devices, as well as iPhones. One in three physicians in the US uses Epocrates mobile or web-based software, according to the company's website.

Emerging Solutions in Pain, a division of MediCom Worldwide, launched an iPhone app for docs working in pain management and addiction earlier in the week. That application is also free, and provides journal summaries, clinical trial results and an ESP radio function, but is only available on the iPhone.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...